

Log of updates to website & data

- Aug 28, 2021 New website live.
- Sep 18, 2021 New data for antibodies & cellular therapies network uploaded.
- Oct 1, 2021 Error in number of trials and participants reporting direct evidence for transfusion related acute lung injury for the comparison convalescent plasma vs. standard care/placebo corrected.
- Oct 2, 2021 Error in reasons for GRADE rating corrected for the following outcomes in antibodies & cellular therapies network: adverse events leading to discontinuation, mechanical ventilation, transfusion-related acute lung injury transfusion-associated circulatory overload, length of hospital stay.
- Oct 12, 2021 Website features upgraded, including: tags to indicate addition of new trials to meta-analysis, social media share buttons, PDF export feature for summary of findings tables, publications page.
- Oct 26, 2021 New trials added to drug treatment network summary of findings tables. Data for summary of effects table forthcoming.
- Nov 1, 2021 The following changes were made:
- GRADE ratings for all indirect and network estimates for drug treatment summary of findings tables updated.
 - Errors in data import in drug treatment summary of findings tables corrected.
- We performed a second NMA to compare the efficacy of different JAK inhibitors. The following nodes were included in the network: baricitinib, ruxolitinib, tofacitinib, corticosteroids + IL6 receptor antagonists, standard care/placebo. Results from this second NMA uploaded. Please select drugs with an asterisk (*) from the drop-down menus to see summary of findings tables.
- Nov 8, 2021 During the previous upload of results for the drug treatments network, GRADE ratings for some indirect comparisons did not appear in the summary of findings tables. This issue affected the following outcomes: mortality, mechanical ventilation, adverse events leading to discontinuation, time to symptom resolution. The issue has now been resolved.